Day One Biopharmaceuticals (DAWN) Common Equity (2022 - 2025)
Historic Common Equity for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $450.9 million.
- Day One Biopharmaceuticals' Common Equity fell 1883.02% to $450.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $450.9 million, marking a year-over-year decrease of 1883.02%. This contributed to the annual value of $502.8 million for FY2024, which is 4507.73% up from last year.
- Per Day One Biopharmaceuticals' latest filing, its Common Equity stood at $450.9 million for Q3 2025, which was down 1883.02% from $460.8 million recorded in Q2 2025.
- Day One Biopharmaceuticals' 5-year Common Equity high stood at $555.5 million for Q3 2024, and its period low was $259.6 million during Q1 2022.
- In the last 4 years, Day One Biopharmaceuticals' Common Equity had a median value of $389.6 million in 2023 and averaged $390.7 million.
- In the last 5 years, Day One Biopharmaceuticals' Common Equity plummeted by 2800.65% in 2024 and then skyrocketed by 6155.74% in 2025.
- Quarter analysis of 4 years shows Day One Biopharmaceuticals' Common Equity stood at $332.0 million in 2022, then increased by 4.37% to $346.5 million in 2023, then soared by 45.08% to $502.8 million in 2024, then fell by 10.32% to $450.9 million in 2025.
- Its Common Equity was $450.9 million in Q3 2025, compared to $460.8 million in Q2 2025 and $479.5 million in Q1 2025.